Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Partial least squares regression (PLS1 and PLS2) and GOLPE variable selection procedures were used for the
treatment of differential pulse polarographic and UV spectrophotometric data obtained from the analysis of the
therapeutic combination of metronidazole and pefloxacin. The analytical method used for the determination was
set up using experimental design strategies (Doehlerts design, full factorial design, fractional face center cube
design, etc.) and by involving the simultaneous optimization of several responses (desirability function). Method
validation was also performed, determining accuracy, precision, linearity and range, detection and quantification
limits and robustness. The quantitative prediction abilities in determining metronidazole and pefloxacin plasma
levels of the PLS1 and PLS2 models were tested on spiked plasma samples and good results were obtained
(metronidazole, 97.5%, RSD = 4.8%, n = 3; pefloxacin, 100.6%, RSD = 3.6%, n = 3 ). The use of multivariate
calibration was particularly useful for spectrophotometric quantification because of the highly overlapping spectra
of the binary mixture.
Introduction
Pefloxacin (P) and metronidazole (M) are well-known antimicrobial agents used in combination in therapy for the
treatment of intra-abdominal infections due to aerobic (P) and
anaerobic (M) bacteria.1 This circumstance makes their plasma
determination very useful and interesting, also considering that
there are no techniques in the literature which report the
simultaneous assay of both drugs in this medium.
Among many existing analytical techniques, the structural
characteristics of the two molecules make them suitable for
polarographic determination. Moreover, the plasma concentrations of P and M allow the differential pulse polarographic
technique (DPP) to be successful in quantification. The
presence of the nitro group in M and of the carbonyl group in P
(Fig. 1) give rise to well-defined polarographic signals,2,3 which
do not overlap, at 2450 and 21410 mV vs. Ag/AgCl,
respectively.
Quantification was performed by multivariate calibration
using suitable predictive variables in order to find a better
1683
Experimental
Reagents
Metronidazole was obtained from Sigma (Milan, Italy) and
pefloxacin was kindly supplied by Formenti (Milan, Italy). Both
drugs were used with no further purification.
Stock standard solutions of each drug in Milli-Q grade water
(M, 0.5 mg mL21) and in 0.05 mol L21 NaOH (P, 1 mg mL21)
were prepared weekly by weighing; solubilization was assisted
by sonicating for a few minutes. All other chemicals used were
of analytical-reagent grade.
Plasma was obtained from the Banca Militare del Sangue
(Florence, Italy).
Apparatus
The electrochemical equipment consisted of a computercontrolled polarographic analyzer (Amel Model 433) comprised of a three-electrode cell with Ag/AgCl reference
electrode, a platinum wire as auxiliary electrode and a dropping
mercury electrode as working electrode. The system was
controlled via a VAAS PC Pentium processor.
UV spectra were acquired in duplicate with a computercontrolled Perkin-Elmer (Monza, Italy) Lambda 2 double-beam
UVvisible spectrophotometer with 1 cm quartz cells.
Nemrod software v. 3.0 from LPRAI (Universit de
Marseille III, Marseille Le Merlan, France) was used for the
generation and evaluation of the statistical experimental
design.
Both spectrophotometric and polarographic data were processed using the PLS algorithm and the procedure of variable
selection included in the software package GOLPE 3.0.
Polarography
Polarographic investigations were carried out by deareating 10
mL of pH 7.4 BrittonWelford buffer (supporting electrolyte)
with highly purified nitrogen for 10 min. For each solution
examined, scans were performed twice and measurements were
made at 9 mV intervals in the range from 2250 to 21650 mV
using the differential pulse polarographic technique with the
following optimized experimental conditions: potential amplitude, 253 mV; pulse increment, 9 mV; and dropping size, 34
a.u. (arbitrary units). Peak potentials occurred at 2450 and
21450 mV for M and P, respectively.
Spectrophotometry
All measurements were made at 1 nm intervals in the 200400
nm region using a 60 nm min21 scan speed.
Level
Concentration
Plasma analysis
Polarography. Calibration model. In order to not exceed
the plasma level concentration of both M and P,1 and in order to
respect the linearity range found for both drugs [also considering the constraints given by the + and 2 levels of the full
factorial design (FFD) used for the construction of the
calibration model], the following procedure was carried out. A
1684
+
P
2
0
+
In the case under study, once the key factors (xi), both
instrumental and otherwise, were established affecting the
differential pulse polarographic procedure of quantification,
their number was not so high (four) to suggest the use of a
screening design. On the contrary, with few variables the study
of the response surface could be undertaken directly. It allowed
a second-order model to be obtained. This model is useful for
predicting the behaviour of the studied system (the y-dependent
variable values of the model) for any values of the x-variables
(independent variables). The true function f relating y to the
design factors is unknown but it is assumed that in the region of
interest (the selected experimental domain) f is well approximated by a low-order polynomial (second-order):
n
y = b0 +
bi xi` +
i =1
i =1
j =1
i j
bij xi x j` +
bij x 2i
(1)
i =1
response. The ANOVA tables both for M1 and P show that the
regression is significant (at least one parameter in the model,
other than b0, is significantly different from 0) and the two
different values s12 and s22 are actually estimates of the same
experimental variance s 2. In other words, the postulated models
are good, that is, they provide an adequate approximation of the
true systems in the investigated experimental domain. From
these models one can extract the best independent set of
conditions for both M1 and P. However, since the goal is the
simultaneous optimization of responses, that is, to obtain a
desirable combination of properties, P and M1 are transformed
into a single desirability function, D, which is then submitted to
optimization.
The desirability function involves the transformation of each
estimated response, P and M1, into a desirability value, di, which
increases as the desirability of the corresponding response
increases.9 The response transformations considered belong to
the class of one-sided transformations. In particular, dP
increases as P increases while dM1 decreases as M1 increases,
with M1 = 1/M, and aiming at the maximization of both the P
and M signals.
The individual desirabilities dP and dM1 thus obtained are then
combined into the D function giving a different importance to
each of them due to the lower polarographic signal of P as
compared with that of M at the working concentration levels
(plasma concentrations) and also considering the noise that the
hydrogen ion reduction wave causes in the P signal. In fact, this
reduction occurs at potential values not far from the P peak
potential. As a consequence, the combined function, D,
takes the form D = 3 dM dP 2 , where dP assumes a double
1
importance compared with dM1. Once the D function is defined,
the algorithm employed by the Nemrod software searches
through the levels of variables (x1x4) to find the optimum value
for D. The resulting optimum conditions are reported in Fig. 2,
which also shows the graphic representation of D.
Calibration model and quantification
In order to avoid interference effects produced by the plasma
matrix, a multivariate calibration method to correlate the
polarographic and UV spectrophotometric data with P and M
concentrations was used. In so doing, the response is described,
quantified and characterized by a multitude of variables
(multivariate characterization). The projection of this multitude
of measurements will provide a better response variable than a
single measurement.10
For both polarographic and spectrophotometric quantification, the model was developed using 11 samples whose
concentrations fit a two-level full factorial design (4 3 2 + 3
replications at the center point) as the training set in order to
allow this set of objects to span the experimental region
properly and obtain a model with good predictive properties in
(2)
1685
Method validation4,5,14
The development and validation of a new analytical method is
an iterative process. In order to determine if the developed
1686
PLS1
Polarography
Spectrophotometry
PLS2
Polarography
Spectrophotometry
SDEC
SDEP
R2
0.0743
0.1407
0.095
0.202
0.997
0.996
0.994
0.993
0.1076
0.2502
0.1421
0.3713
0.993
0.989
0.988
0.976
0.058
0.070
0.082
0.095
0.988
0.999
0.996
0.999
Analyte
Equation of line
(y in nA, x in mg mL21)
R2
DL/mg mL
0.300
0.086
0.335
0.106
0.949
0.999
0.937
0.998
M
P
y = 1.16x + 0.095
y = 0.172x + 0.064
0.994
0.990
0.133
0.250
Q2
Table 4 Linearity range and detection limit (DL) validation parameters for
the simultaneous polarographic determination of M and P
Recovery (%)
RSD (%) (n = 3)
Ma
Table 6
50
105.3
3.1
100
97.5
4.8
150
102.0
2.4
50
108.3
3.3
Pb
100
100.6
3.6
150
105.0
3.8
a Test concentration 2 mg mL21. b Test concentration 5 mg mL21.
Analyst
Source of variation
Sum of squares
Degrees of freedom
Mean square
Regression
Residual
Lack of fit
Pure error
Total
Regression
Residual
Lack of fit
Pure error
Total
0.75643
0.10272
0.10227
0.00045
0.85915
0.10740
0.01399
0.01274
0.00125
0.12139
10
6
5
1
16
10
16
5
1
16
0.07564
0.01712
0.02045
0.00045
Table 7
0.01074
0.00233
0.00255
0.00125
F0
Significance (%)
4.42
<5
45.45
11.7
4.60
<5
2.04
48.1
Analyst
Source of variation
Sum of squares
Degrees of freedom
Mean square
F0
Significance (%)
Regression
Residual
Lack of fit
Pure error
Total
Regression
Residual
Lack of fit
Pure error
Total
0.29331
0.09754
0.05642
0.041113
0.3905
0.04224
0.02485
0.00928
0.01557
0.06709
11
8
5
3
19
11
8
5
3
19
0.02666
0.01219
0.01128
0.01371
2.19
13.8
0.82
60.5
0.00384
0.00311
0.00186
0.00519
1.24
39.0
0.36
85.2
1687
Acknowledgement
This work was supported by a grant from the Italian Ministry of
the University.
1688
References
1 Swedish Study Group, J. Antimicrob. Chemother., 1990, 26, 173.
2 A. M. Y. Jaber and A. Lounici, Anal. Chim. Acta, 1994, 291, 53.
3 A. Z. Abu Zuhri, S. I. Al-Khalil and M. S. Suleiman, Anal. Lett.,
1986, 19, 453.
4 Third International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use.
Draft Guidelines on Validation of Analytical Procedures: Methodology, Yokohama, Japan, 29 November1 December 1995.
5 United States Pharmacopeia, 23rd Revision, US Pharmaceutical
Convention, Rockville, MD, 1995, pp. 19821984.
6 S. Wold, J. Pharm. Biomed. Anal., 1991, 9, 589.
7 P. Gratteri, S. Furlanetto, E. La Porta, S. Pinzauti and R. Leardi,
Farmaco, 1996, 51, 231.
8 P. D. Haaland, Experimental Design in Biotechnology, Marcel
Dekker, New York, 1989.
9 G. Derringer and R. Suich, J. Qual. Technol., 1980, 12, 214.
10 S. Wold, M. Sjstrm, R. Carlson, T. Lundstedt, S. Hellberg, B.
Skagerberg, C. Wikstrm and J. hman, Anal. Chim. Acta, 1986, 191,
17.
11 M. Baroni, G. Costantino, G. Cruciani, D. Riganelli, R. Valigi and S.
Clementi, Quant. StructAct. Relat., 1993, 12, 9.
12 S. Wold, Technometrics, 1978, 20, 397.
13 G. Cruciani, M. Baroni, S. Clementi, G. Costantino, D. Riganelli and
B. Skagerberg, J. Chemom., 1992, 6, 335.
14 J. M. Green, Anal. Chem., 1996, 68, 305A.
15 J. C. Miller and J. N. Miller, Statistics for Analytical Chemistry,
Wiley, New York, 3rd edn., 1993.
Paper 9/05038H